AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

Temab-A is described as an investigational, next-generation c-Met-directed antibody-drug conjugate carrying a novel topoisomerase 1 inhibitor. It is being studied in advanced solid tumors, including colorectal cancer and non-small cell lung cancer; the provided excerpt ends before explaining the referenced designations or reporting clinical results.